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Dilated  cardiomyopathy  (DCM),  a leading  cause  of  heart
failure  and  sudden  cardiac  death,  is  characterized  by  ven-
tricular  dilatation  and  impaired  systolic  function  in the
absence  of  abnormal  loading  conditions  or  coronary  artery
disease.1 Its  prevalence  is  approximately  1 in 2500  individ-
uals,  and  30-50%  of  cases  are familial.1
Familial  DCM  is  a predominantly  autosomal  disease
with  dominant  transmission,  although  autosomal  recessive,
X-linked  and mitochondrial  patterns  of inheritance  have  also
been  described.2 In  familial  DCM,  nearly  60%  of  cases  display
some  form  of  mutation  in  one  of  more  than 60  genes  asso-
ciated  with  DCM.3 Pathogenic  variants  in the  gene  coding
for  the  titin  protein  (TTN) appear  to  be  the main  cause  of
familial  DCM,  being  reported  in 12-25%  of  cases.3--5 The  sec-
ond  most  prevalent  gene  in familial  DCM  (LMNA) codes  for
lamin  A/C,  variants  of  which  are  found  in around  10-15%  of
cases.6,7 DCM  patients  with  LMNA  mutations  are reported
to  have  worse  prognosis  and  more  serious  cardiovascular
complications,  including  sudden  cardiac  death  and  a higher
rate  of  heart  transplantation  (HT),  compared  to  individ-
uals  with  idiopathic  DCM.8 Other  genes,  including  those
for  beta-myosin  heavy  chain  7 (MYH7), cardiac  troponin
T  type  2  (TNNT2),  RNA-binding  motif  protein  20  (RBM20),
Bcl2-associated  athanogene  3 (BAG3), tropomyosin  alpha-1
(TPM1),  desmoplakin  (DSP), calcium/sodium-handling  pro-
teins  of  sodium  channel  type V alpha  subunit  (SCN5A),
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cardiac  muscle  alpha  actin  1 (ACTC1)  and  cardiac  myosin-
binding  protein  C  (MYBPC3), appear  to  be  involved  in 5-10%
cases  of  familial  DCM.8 This  genetic  diversity  in  DCM  has
significant  implications  for  molecular  diagnosis  and  clinical
genetic  counseling.
DCM  can  progress  to  a terminal  stage  due  to various
factors  such  as  the  aggressiveness  of the disease,  late  initi-
ation  of  pharmacotherapy,  or, especially,  the presence  of  an
adverse  genetic  background  and  its  relationship  with  envi-
ronmental  factors.  These  patients  may  eventually  progress
to  HT,  regardless  of therapy.  In this context,  genetic  charac-
terization  can be a useful  tool  to  determine  the mechanisms
that  result  in failure  to  respond  to  heart  failure  therapies
and  progression  to  terminal  disease.
In the  current  issue  of  the Journal, Martins  et  al.9 analyze
thirteen  HT  recipients  with  end-stage  DCM.  In this  group,
they  screened  for  mutations  in  15  genes  --  LMNA/C,  MYH7,
MYBPC3,  TNNT2, ACTA1, TPM1,  CSRP3, TCAP, SGCD, PLN,
MYL2,  MYL3, TNNI3, TAZ  and  LDB3. The  genetic  character-
ization  was  carried  out  using  next-generation  sequencing
(NGS),  which  identified  nine  variants  in six  (46%)  patients:
five  in  LMNA, two  in LBD3, one  in TNNT2  and one  in  TCAP.
Most  of  these  variations  were  considered  non-pathogenic
or  of  uncertain  significance,  except  for  one  variant  in
LMNA  that  was  classified  as  likely  pathogenic  (c.1003C>T;
p.Arg335Trp).
The study  by  Martins  et  al.  presents  some  limitations  that
are  clearly  stated  by  the authors,  including  the small  num-
bers  of patients  and  of  genes  studied,  which limit  the study’s
conclusions.  Nevertheless,  the  paper  accurately  depicts  the
genetic  variation  of DCM-related  genes  in a  Portuguese
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patient  cohort  and  highlights  the importance  of  genetic
characterization  in HT recipients  due to  end-stage  DCM,
stressing  the  need  for further  studies.
Previously,  clinical  genetic  testing  was  mainly  based  on
conventional  molecular  techniques  like  Sanger  sequencing,
but  recent  advances  in  DNA  and RNA sequencing  technology
mean  that  larger  numbers  of  genes  can now  be  studied
simultaneously.10 The  high-throughput  sequencing  methods
of  NGS  are  able  to  rapidly  analyze  a large  number  of
genetic  loci and  samples.  The  data  thus  generated  provide
researchers  and  clinicians  with  an assortment  of  tools  to
study  genomes  in greater  depth  and  can  lead  to  a  better
understanding  of  genomic  variation,  phenotype  and  disease.
Consequently,  whole-exome  and  genome  sequencing  for
clinical  screening  are  currently  entering  clinical  practice  in
various  medical  specialties,  particularly  in cardiology.10 The
application  of  NGS  technology  in genetic  analysis,  together
with  a  better  knowledge  of  the  DCM  phenotype,  will  help  to
improve  diagnosis,  prognosis  and  risk  stratification.  It may
contribute  to  our knowledge  of  the  genetic  mechanisms  of
cardiomyopathies  that  do  not respond  to  medical  therapy,
which  includes  DCM  patients  undergoing  HT.
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